Top Markets
#1 Prom Prom +32.17%
#2 QuantixAI QuantixAI +31.15%
#3 Velvet Velvet +29.00%
#4 MowCat MowCat +28.71%
#5 Tutorial Tutorial +25.72%
#6 UnifAI Network UnifAI Network +23.74%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +21.78%
#8 MarsCoin MarsCoin +18.77%
#9 Versatize Coin Versatize Coin +16.65%
#10 Kinesis Silver Kinesis Silver +14.47%
Coin of the day
Prom Prom
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Sunho Biologics, Inc. Sunho Biologics, Inc.

Sunho Biologics, Inc.

2898
Classement en actions #20682
Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering,... Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market biological therapies. These treatments are designed to influence the body's immune system, both its inherent and adaptive responses, thereby altering the immune microenvironment. Among its portfolio is IAH0968, a monoclonal antibody specifically engineered to enhance antibody-dependent cell-mediated cytotoxicity, currently undergoing Phase II clinical trials for the treatment of biliary tract carcinoma and colorectal cancer. The company also develops IAP0971 and IAE0972, a pair of immunocytokines that have successfully concluded Phase I clinical trials for various advanced solid tumors, notably non-small cell lung cancer and colorectal cancer. Sunho Biologics also boasts a robust pipeline of early-stage assets. These include IBB0979, an immunocytokine targeting solid tumors; IBC0966, a dual-action fusion protein (anti-PD-L1 antibody-signal regulatory protein) in clinical development, designed to elicit tumor-specific immune responses; IBD0333, aimed at tumor cells; IAN0982, another oncology candidate; and immunosuppressants ISH0988 and ISH0613, which are being explored for autoimmune conditions. Established in 2018, the company operates from its headquarters in Huzhou, China, and functions as a subsidiary of Sunho Wisdom Investments Limited.
Prix de l'action
$0.81744861
Dernière synchronisation: 2026-04-02
Capitalisation boursière
$124.61M
Changement (1 jour)
0.00%
Changement (1 an)
-7.82%
Pays
CN
Échange Sunho Biologics, Inc. (2898)

Catégorie

Healthcare
Revenus pour Sunho Biologics, Inc. (2898)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Sunho Biologics, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Sunho Biologics, Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH